Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA therapy in progressive adenoid cystic carcinoma of the salivary glands
2026-525776-26-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in adenoid cystic carcinoma (ACC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Objective response rate. Planned start Aug 2026; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on 2026-525776-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525776-26-00.